UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 583

Sortiert nach

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2020-02, Vol.43 (2), p.487-493

2020

Volltextzugriff (PDF)

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetologia, 2020-02, Vol.63 (2), p.221-228

2020

Volltextzugriff (PDF)

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2018-12, Vol.41 (12), p.2669-2701

2018

Volltextzugriff (PDF)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2022-11, Vol.45 (11), p.2753-2786

2022

Volltextzugriff (PDF)

COVID-19, Hyperglycemia, and New-Onset Diabetes

Diabetes care, 2021-12, Vol.44 (12), p.2645-2655

2021

Volltextzugriff (PDF)

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Diabetes care, 2015-01, Vol.38 (1), p.140-149

2015

Volltextzugriff (PDF)

Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery

Proceedings of the National Academy of Sciences - PNAS, 2015-07, Vol.112 (27), p.8260-8265

2015

Volltextzugriff (PDF)

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

Diabetes care, 2018-06, Vol.41 (6), p.1196-1203

2018

Volltextzugriff (PDF)

Real-world evidence: the devil is in the detail

Diabetologia, 2020-09, Vol.63 (9), p.1694-1705

2020

Volltextzugriff (PDF)

Synthetic beta cells for fusion-mediated dynamic insulin secretion

Nature chemical biology, 2018-01, Vol.14 (1), p.86

2018

Volltextzugriff (PDF)

Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

Nature biomedical engineering, 2020-05, Vol.4 (5), p.499

2020

Volltextzugriff (PDF)

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience

Diabetes care, 2018-08, Vol.41 (8), p.1783-1791

2018

Volltextzugriff (PDF)

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care

The lancet. Diabetes & endocrinology, 2021-01, Vol.9 (1), p.46-52

2021

Volltextzugriff (PDF)

Dual self-regulated delivery of insulin and glucagon by a hybrid patch

Proceedings of the National Academy of Sciences - PNAS, 2020-11, Vol.117 (47), p.29512-29517

2020

Volltextzugriff (PDF)

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)

Diabetes care, 2014-11, Vol.37 (11), p.2926-2933

2014

Volltextzugriff (PDF)

Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin

Biomacromolecules, 2014-10, Vol.15 (10), p.3495-3502

2014

Volltextzugriff (PDF)

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Diabetes care, 2013-08, Vol.36 (8), p.2254-2261

2013

Volltextzugriff (PDF)

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Diabetes, obesity & metabolism, 2019-10, Vol.21 (10), p.2203-2210

2019

Volltextzugriff (PDF)

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

The Lancet (British edition), 2009-07, Vol.374 (9683), p.39-47

2009

Volltextzugriff (PDF)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Diabetes care, 2009-07, Vol.32 (7), p.1224-1230

2009

Volltextzugriff (PDF)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Diabetes care, 2015-07, Vol.38 (7), p.1181-1188

2015

Volltextzugriff (PDF)

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

The Lancet (British edition), 2008-10, Vol.372 (9645), p.1240-1250

2008

Volltextzugriff (PDF)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

The Lancet (British edition), 2013-01, Vol.381 (9861), p.117-124

2013

Volltextzugriff (PDF)

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Diabetologia, 2018-01, Vol.61 (1), p.58-65

2018

Volltextzugriff (PDF)

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum

Diabetes care, 2016-07, Vol.39 (7), p.1186-1201

2016

Volltextzugriff (PDF)

1 – 25 von 583

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(526)
Mit Volltextzugriff
(523)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(382)
Life Sciences & Biomedicine
(361)
Humans
(319)
Diabetes
(277)
Endocrinology & Metabolism
(196)
Male
(186)
Female
(179)
Diabetes Mellitus
(158)
Diabetes Mellitus, Type 2 - Drug Therapy
(155)
Middle Aged
(153)
Aged
(129)
Hypoglycemic Agents - Therapeutic Use
(114)
Insulin
(103)
Risk Factors
(94)
Clinical Trials
(85)
Glucose
(84)
Cardiovascular Disease
(78)
Adult
(74)
Patients
(72)
Biological And Medical Sciences
(69)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

COVID-19, Hyperglycemia, and New-Onset Diabetes

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

Real-world evidence: the devil is in the detail

Synthetic beta cells for fusion-mediated dynamic insulin secretion

Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care

Dual self-regulated delivery of insulin and glucagon by a hybrid patch

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)

Bio-Inspired Synthetic Nanovesicles for Glucose-Responsive Release of Insulin

Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum

Suchergebnisse filtern